Cognition Therapeutics

Cognition Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for neurodegenerative diseases like Alzheimer's and dementia with Lewy bodies. Their lead investigational drug, Zervimesine (CT1812), is designed to protect brain synapses and prevent neuronal decline through a once-daily oral therapy.